Literature DB >> 14601280

Terlipressin infusion in catecholamine-resistant shock.

D H Jolley1, B L De Keulenaer, A Potter, D P Stephens.   

Abstract

Catecholamine-resistant shock is not uncommon in intensive care. Bolus dose terlipressin (a vasopressin analogue) has been used successfully in this setting allowing cessation of other vasopressor agents. The relative vasopressin deficiency in combination with the restoration of the vascular tone (by blocking adenosine triphosphate potassium-sensitive channels) by exogenous vasopressin may be the explanation of these beneficial effects. We describe a case report where the use of a continuous terlipressin infusion was associated with a dramatic improvement. To our knowledge there have been no previous reports of the use of terlipressin by continuous infusion for the treatment of catecholamine-resistant shock.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601280     DOI: 10.1177/0310057X0303100532

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  7 in total

1.  Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?

Authors:  Andrea Morelli; Christian Ertmer; Matthias Lange; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-05-25       Impact factor: 17.440

Review 2.  [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].

Authors:  C Ertmer; A W Sielenkämper; H van Aken; H-G Bone; M Westphal
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

3.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

4.  Current place of vasopressin analogues in the treatment of septic shock.

Authors:  Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Martin Westphal
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

Review 5.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

6.  Using terlipressin in a pediatric patient with septic shock resistant to catecholamines.

Authors:  Seher Erdogan; Mehmet Bosnak
Journal:  North Clin Istanb       Date:  2017-11-01

7.  Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis.

Authors:  Po Huang; Yuhong Guo; Bo Li; Qingquan Liu
Journal:  Front Pharmacol       Date:  2019-12-23       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.